What’s happening?
Novo Nordisk, the manufacturer of Ozempic and Wegovy, is now testing semaglutide in two phase 3 clinical trials to assess whether the drug can slow the progression of Alzheimer’s.
Each trial includes around 1,800 patients. One focuses on those with early-stage Alzheimer’s, while the other looks at patients who have mild cognitive impairment.
The research is part of a wider push to explore the neuroprotective benefits of GLP-1 drugs, which were originally developed for diabetes and now dominate the weight loss market.
SlimrChat’s view
We’ve already reported on the link between GLP-1 drugs like Mounjaro and a lower risk of developing dementia. Now, Novo Nordisk is testing whether similar drugs might go even further – not just protecting the brain, but treating Alzheimer’s directly.
Read: Mounjaro linked to lower dementia risk
It’s early days, but for those of us who’ve seen first hand the toll of cognitive decline, even the possibility of a breakthrough is something worth watching closely.
